董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrea Biffi | 男 | Director | 35 | 1.34万美元 | 未持股 | 2017-04-10 |
| William N. Kelley | 男 | Director | 77 | 1.67万美元 | 未持股 | 2017-04-10 |
| Jane H. Hsiao | 女 | Director | 69 | 1.34万美元 | 未持股 | 2017-04-10 |
| Richard C. Pfenniger, Jr. | 男 | Director | 61 | 1.67万美元 | 未持股 | 2017-04-10 |
| Aftab R. Kherani | 男 | Director | 43 | 1.34万美元 | 未持股 | 2017-04-10 |
| Paul A. LaViolette | 男 | Chairman of the Board | 59 | 2.00万美元 | 未持股 | 2017-04-10 |
| David B. Milne | 男 | Director | 54 | 1.34万美元 | 未持股 | 2017-04-10 |
| Todd M. Pope | 男 | Chief Executive Officer, President and Director | 51 | 223.35万美元 | 未持股 | 2017-04-10 |
| William N. Starling | 男 | Director | 63 | 1.67万美元 | 未持股 | 2017-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony Fernando | 男 | Chief Technology Officer | 45 | 131.80万美元 | 未持股 | 2017-04-10 |
| Joseph P. Slattery | 男 | Executive Vice President and Chief Financial Officer | 52 | 134.54万美元 | 未持股 | 2017-04-10 |
| Todd M. Pope | 男 | Chief Executive Officer, President and Director | 51 | 223.35万美元 | 未持股 | 2017-04-10 |
董事简历
中英对照 | 中文 | 英文- Andrea Biffi
-
Andrea Biffi目前是SOFAR S.p.A.的首席执行官，自2015年6月以来一直担任该职位；并自2012年11月起担任SOFAR S.p.A. 的董事会成员。Biffi先生自2008年1月起曾在SOFAR或 SOFAR拥有的所有公司任职。 成为首席执行官之前，2012年11月至2015年6月，Biffi先生担任SOFAR的总经理。2008年1月至2013年11月，Biffi先生担任SOVETA BALTICA UAB（SOFAR的一家立陶宛子公司）的总经理。 自2013年2月成立以来，Biffi先生担任SOFAR SWISS S.A.的首席执行官兼总裁，自2016年3月起担任SOFAR AMERICAS Inc.的董事会主席。
Andrea Biffi is currently the Chief Executive Officer of Sofar S.p.A., a position he has held since June 2015 and he has served as a member of the Board of Directors of Sofar S.p.A. since November 2012. Mr. Biffi has worked for Sofar, or companies owned by Sofar, since January 2008. Prior to becoming Chief Executive Officer, Mr. Biffi was General Manager of Sofar from November 2012 until June 2015. From January 2008 until November 2013 Mr. Biffi served as General Manager of SOVETA BALTICA UAB, a Lithuanian subsidiary of Sofar. Since the date of its incorporation in February 2013 Mr. Biffi has served as CEO and President of Sofar SWISS S.A. and since March 2016 Chairman of the Board of Directors of Sofar Americas Inc. - Andrea Biffi目前是SOFAR S.p.A.的首席执行官，自2015年6月以来一直担任该职位；并自2012年11月起担任SOFAR S.p.A. 的董事会成员。Biffi先生自2008年1月起曾在SOFAR或 SOFAR拥有的所有公司任职。 成为首席执行官之前，2012年11月至2015年6月，Biffi先生担任SOFAR的总经理。2008年1月至2013年11月，Biffi先生担任SOVETA BALTICA UAB（SOFAR的一家立陶宛子公司）的总经理。 自2013年2月成立以来，Biffi先生担任SOFAR SWISS S.A.的首席执行官兼总裁，自2016年3月起担任SOFAR AMERICAS Inc.的董事会主席。
- Andrea Biffi is currently the Chief Executive Officer of Sofar S.p.A., a position he has held since June 2015 and he has served as a member of the Board of Directors of Sofar S.p.A. since November 2012. Mr. Biffi has worked for Sofar, or companies owned by Sofar, since January 2008. Prior to becoming Chief Executive Officer, Mr. Biffi was General Manager of Sofar from November 2012 until June 2015. From January 2008 until November 2013 Mr. Biffi served as General Manager of SOVETA BALTICA UAB, a Lithuanian subsidiary of Sofar. Since the date of its incorporation in February 2013 Mr. Biffi has served as CEO and President of Sofar SWISS S.A. and since March 2016 Chairman of the Board of Directors of Sofar Americas Inc.
- William N. Kelley
-
William N. Kelley, 他是医学博士，并担任GenVec公司的董事（2002年6月以来）。他是薪酬委员会的成员,以及公司提名和治理委员会的主席。他给董事会带来长期参与基因治疗的实验模型。他和他的同事们在密歇根大学是今天公认的第一个提出体内基因治疗的,也是第一个直接管理一个人类基因体内并获得表达的实验动物模型。从1989年到2000年，他担任宾夕法尼亚大学的执行副总裁，以及医疗中心的首席执行官、医学院的院长、医学和生物化学和生物物理学教授。他于1993年成为宾夕法尼亚大学的卫生保健系统的首席执行官（自成立以来）。他目前是宾夕法尼亚大学的医学院医学教授。他曾担任美国社会临床调查的总裁、美国风湿病学会的总裁、美国内科医学委员会主席和居住审查委员会内科主席。他目前是Indian River Medical Center的董事。在过去的五年中,他曾任职Merck & Co公司、 Beckman Coutler公司、Advanced Bio-Surfaces公司和 PolyMedix公司的董事会。
William N. Kelley is currently Professor of Medicine at the School of Medicine of the University of Pennsylvania. He is also a director of GenVec, Inc., since June 2002. From 1989 to 2000 Dr. Kelley served as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center, founding CEO of the University of Pennsylvania Health System, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. In the national leadership arena, Dr. Kelley has served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Within the past five years, Dr. Kelley served on the board of directors of Merck & Co. Inc. and Beckman Coulter, Inc. - William N. Kelley, 他是医学博士，并担任GenVec公司的董事（2002年6月以来）。他是薪酬委员会的成员,以及公司提名和治理委员会的主席。他给董事会带来长期参与基因治疗的实验模型。他和他的同事们在密歇根大学是今天公认的第一个提出体内基因治疗的,也是第一个直接管理一个人类基因体内并获得表达的实验动物模型。从1989年到2000年，他担任宾夕法尼亚大学的执行副总裁，以及医疗中心的首席执行官、医学院的院长、医学和生物化学和生物物理学教授。他于1993年成为宾夕法尼亚大学的卫生保健系统的首席执行官（自成立以来）。他目前是宾夕法尼亚大学的医学院医学教授。他曾担任美国社会临床调查的总裁、美国风湿病学会的总裁、美国内科医学委员会主席和居住审查委员会内科主席。他目前是Indian River Medical Center的董事。在过去的五年中,他曾任职Merck & Co公司、 Beckman Coutler公司、Advanced Bio-Surfaces公司和 PolyMedix公司的董事会。
- William N. Kelley is currently Professor of Medicine at the School of Medicine of the University of Pennsylvania. He is also a director of GenVec, Inc., since June 2002. From 1989 to 2000 Dr. Kelley served as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center, founding CEO of the University of Pennsylvania Health System, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. In the national leadership arena, Dr. Kelley has served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Within the past five years, Dr. Kelley served on the board of directors of Merck & Co. Inc. and Beckman Coulter, Inc.
- Jane H. Hsiao
-
Jane H. Hsiao， 她是哲学博士，拥有工商管理硕士学位。她曾一直担任公司的副主席兼首席技术官（2007年5月以来）。她曾担任IVAX公司的技术事务副主席（从1995年到2006年1月）。她曾担任IVAX Animal Health公司（IVAX公司的兽医产品子公司）董事长、首席执行官和总裁（从1998年到2006年）。她曾一直担任Non-Invasive Monitoring Systems公司（OTCBB:NIMU）（一个医疗设备公司）的董事会主席（2008年10月以来），并于2012年2月被任命为Non-Invasive Monitoring Systems公司的临时首席执行官。她也是董事，任职于TransEnterix(OTCBB:TRXC)（一个医疗设备公司）、Neovasc公司(TSXV:NVC)（一个公司开发和营销医学专业血管设备）、Biozone Pharmaceuticals公司(OTCBB:BZNE)（生物技术公司开发抗病毒治疗人类疾病）。她此前曾担任Sorrento Therapeutics公司(OTCBB:SRNE)（发展阶段生物制药公司）、PROLOR Biotech公司的董事（2013年8月被公司收购之前）的董事，以及SafeSitch Medical公司（与TransEnterix公司合并之前）的董事会主席。
Jane H. Hsiao has served since May 2007 as Vice-Chairman and Chief Technical Officer of OPKO. Since October 2008 Dr. Hsiao has served as Chairman of the Board and, since February 2012 Interim CEO of medical device developer, Non-Invasive Monitoring Systems, Inc. NIMS. Additionally, Dr. Hsiao serves as a director to Neovasc, Inc., a company developing and marketing medical specialty vascular devices, and Cocrystal Pharma, formerly Biozone Pharmaceuticals, Inc., a publicly traded biotechnology company developing new treatments for viral diseases. Dr. Hsiao previously served as the Vice Chairman-Technical Affairs and Chief Technical Officer of IVAX, from 1995 until IVAX was acquired in January 2006 by Teva. Dr. Hsiao also served as Chairman, CEO and President of IVX Animal Health, IVAX’s veterinary products subsidiary, from 1998 until 2006 and as IVAX’s Chief Regulatory Officer from 1992 to 1995. Dr. Hsiao previously served on the board of directors of Prolor and Sorrento Therapeutics, Inc., a development stage biopharmaceutical company. Dr. Hsiao received her B.S. from National Taiwan University and her Ph.D. from the University of Illinois, Chicago. - Jane H. Hsiao， 她是哲学博士，拥有工商管理硕士学位。她曾一直担任公司的副主席兼首席技术官（2007年5月以来）。她曾担任IVAX公司的技术事务副主席（从1995年到2006年1月）。她曾担任IVAX Animal Health公司（IVAX公司的兽医产品子公司）董事长、首席执行官和总裁（从1998年到2006年）。她曾一直担任Non-Invasive Monitoring Systems公司（OTCBB:NIMU）（一个医疗设备公司）的董事会主席（2008年10月以来），并于2012年2月被任命为Non-Invasive Monitoring Systems公司的临时首席执行官。她也是董事，任职于TransEnterix(OTCBB:TRXC)（一个医疗设备公司）、Neovasc公司(TSXV:NVC)（一个公司开发和营销医学专业血管设备）、Biozone Pharmaceuticals公司(OTCBB:BZNE)（生物技术公司开发抗病毒治疗人类疾病）。她此前曾担任Sorrento Therapeutics公司(OTCBB:SRNE)（发展阶段生物制药公司）、PROLOR Biotech公司的董事（2013年8月被公司收购之前）的董事，以及SafeSitch Medical公司（与TransEnterix公司合并之前）的董事会主席。
- Jane H. Hsiao has served since May 2007 as Vice-Chairman and Chief Technical Officer of OPKO. Since October 2008 Dr. Hsiao has served as Chairman of the Board and, since February 2012 Interim CEO of medical device developer, Non-Invasive Monitoring Systems, Inc. NIMS. Additionally, Dr. Hsiao serves as a director to Neovasc, Inc., a company developing and marketing medical specialty vascular devices, and Cocrystal Pharma, formerly Biozone Pharmaceuticals, Inc., a publicly traded biotechnology company developing new treatments for viral diseases. Dr. Hsiao previously served as the Vice Chairman-Technical Affairs and Chief Technical Officer of IVAX, from 1995 until IVAX was acquired in January 2006 by Teva. Dr. Hsiao also served as Chairman, CEO and President of IVX Animal Health, IVAX’s veterinary products subsidiary, from 1998 until 2006 and as IVAX’s Chief Regulatory Officer from 1992 to 1995. Dr. Hsiao previously served on the board of directors of Prolor and Sorrento Therapeutics, Inc., a development stage biopharmaceutical company. Dr. Hsiao received her B.S. from National Taiwan University and her Ph.D. from the University of Illinois, Chicago.
- Richard C. Pfenniger, Jr.
-
Richard C. Pfenniger, Jr.是公司的董事（2008年1月以来）。他曾担任IntegraMed America公司（一个私营企业，拥有技术医疗行业的高度专业化的门诊中心）的临时首席执行官（从2013年1月到2013年6月）。他曾担任Continucare Corporation（NYSE:CNU）（提供初级保健医生和实践管理服务）的首席执行官兼总裁（从2003年10月到2011年10月），以及Continucare Corporation的董事会主席（从2002年9月到2011年10月）。此前，他曾担任Whitman Education Group公司的首席执行官兼副主席（从1997年到2003年6月）。加入Whitman公司之前，他曾担任IVAX公司的首席运营官（从1994年到1997年），以及IVAX公司的负责法律事务的高级副总裁和法律总顾问（从1989年到1994年）。他目前担任GP Strategies公司(NYSE:GPX)（企业教育和培训公司）、TransEnterix公司(OTCBB:TRXC)（一个医疗设备公司）、IntegraMed America公司的董事。他此前曾担任Safestitch Medical公司的董事（与TransEnterix公司合并之前）。
Richard C. Pfenniger, Jr. is currently a private investor who previously served as a senior executive at several companies. He served as Interim Chief Executive Officer of Vein Clinics of America, Inc. from May 2014 to February 2015 and as Interim Chief Executive Officer of Integramed America, Inc., a manager of outpatient fertility centers, from January to June 2013. From 2003 until 2011 Mr. Pfenniger served as the Chairman of the Board, President and Chief Executive Officer of Continucare Corporation, a provider of primary care physician services. Mr. Pfenniger was the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc., a provider of career-oriented higher education, from 1997 until 2003. From 1994 to 1997 Mr. Pfenniger served as the Chief Operating Officer of IVAX Corporation, and from 1989 to 1994 he served as the Senior Vice President-Legal Affairs and General Counsel of IVAX Corporation, a multi-national pharmaceutical company. Mr. Pfenniger currently serves as a Director of TransEnterix, Inc. a medical device company, Opko Health, Inc. (a multi-national pharmaceutical and diagnostics company) and BioCardia, Inc. (a regenerative medicine company). Mr. Pfenniger also serves as Vice Chairman of the Board of Trustees of the Frost Science Museum in Miami, Florida. Previously, he was a director of Wright Investors' Service Holdings, Inc. Mr. Pfenniger holds a B.B.A. from Florida Atlantic University and a J.D. from the University of Florida. - Richard C. Pfenniger, Jr.是公司的董事（2008年1月以来）。他曾担任IntegraMed America公司（一个私营企业，拥有技术医疗行业的高度专业化的门诊中心）的临时首席执行官（从2013年1月到2013年6月）。他曾担任Continucare Corporation（NYSE:CNU）（提供初级保健医生和实践管理服务）的首席执行官兼总裁（从2003年10月到2011年10月），以及Continucare Corporation的董事会主席（从2002年9月到2011年10月）。此前，他曾担任Whitman Education Group公司的首席执行官兼副主席（从1997年到2003年6月）。加入Whitman公司之前，他曾担任IVAX公司的首席运营官（从1994年到1997年），以及IVAX公司的负责法律事务的高级副总裁和法律总顾问（从1989年到1994年）。他目前担任GP Strategies公司(NYSE:GPX)（企业教育和培训公司）、TransEnterix公司(OTCBB:TRXC)（一个医疗设备公司）、IntegraMed America公司的董事。他此前曾担任Safestitch Medical公司的董事（与TransEnterix公司合并之前）。
- Richard C. Pfenniger, Jr. is currently a private investor who previously served as a senior executive at several companies. He served as Interim Chief Executive Officer of Vein Clinics of America, Inc. from May 2014 to February 2015 and as Interim Chief Executive Officer of Integramed America, Inc., a manager of outpatient fertility centers, from January to June 2013. From 2003 until 2011 Mr. Pfenniger served as the Chairman of the Board, President and Chief Executive Officer of Continucare Corporation, a provider of primary care physician services. Mr. Pfenniger was the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc., a provider of career-oriented higher education, from 1997 until 2003. From 1994 to 1997 Mr. Pfenniger served as the Chief Operating Officer of IVAX Corporation, and from 1989 to 1994 he served as the Senior Vice President-Legal Affairs and General Counsel of IVAX Corporation, a multi-national pharmaceutical company. Mr. Pfenniger currently serves as a Director of TransEnterix, Inc. a medical device company, Opko Health, Inc. (a multi-national pharmaceutical and diagnostics company) and BioCardia, Inc. (a regenerative medicine company). Mr. Pfenniger also serves as Vice Chairman of the Board of Trustees of the Frost Science Museum in Miami, Florida. Previously, he was a director of Wright Investors' Service Holdings, Inc. Mr. Pfenniger holds a B.B.A. from Florida Atlantic University and a J.D. from the University of Florida.
- Aftab R. Kherani
-
Aftab R. Kherani，医学博士。自2008年9月以来担任Aisling Capita的主要负责人。此前曾是McKinsey公司的一位项目经理，是制药、医疗产品和私募股权业务部成员。在McKinsey之前，他曾是Duke大学医疗中心的一位住院总医师，在那完成了他的普通外科实习。曾于2001-2003年期间，在哥伦比亚大学（Columbia University）、内外科学院（College of Physicians & Surgeons）完成他为期两年的博士后研究课程。Kherani博士目前在一家私营公司- T2 Biosystems股份有限公司担任董事会观察员。他是从Duke大学获得他的医学博士学位、生物学学士学位以及经济学学士学位的。
Aftab R. Kherani Since September 2008 Dr. Kherani has served as an investment professional of Aisling Capital, where he is currently a Partner. Previously, Dr. Kherani was an Engagement Manager at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He completed a two-year post-doctoral research fellowship at Columbia University, College of Physicians & Surgeons from 2001 to 2003. Dr. Kherani currently serves as a Director of Spirox, Inc. and as a board observer at EarLens, Inc., a privately-held company. Dr. Kherani is also a board observer at Loxo Oncology, Inc. Dr. Kherani received his M.D. from Duke, and his B.S. in Biology and A.B. in Economics from Duke. - Aftab R. Kherani，医学博士。自2008年9月以来担任Aisling Capita的主要负责人。此前曾是McKinsey公司的一位项目经理，是制药、医疗产品和私募股权业务部成员。在McKinsey之前，他曾是Duke大学医疗中心的一位住院总医师，在那完成了他的普通外科实习。曾于2001-2003年期间，在哥伦比亚大学（Columbia University）、内外科学院（College of Physicians & Surgeons）完成他为期两年的博士后研究课程。Kherani博士目前在一家私营公司- T2 Biosystems股份有限公司担任董事会观察员。他是从Duke大学获得他的医学博士学位、生物学学士学位以及经济学学士学位的。
- Aftab R. Kherani Since September 2008 Dr. Kherani has served as an investment professional of Aisling Capital, where he is currently a Partner. Previously, Dr. Kherani was an Engagement Manager at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He completed a two-year post-doctoral research fellowship at Columbia University, College of Physicians & Surgeons from 2001 to 2003. Dr. Kherani currently serves as a Director of Spirox, Inc. and as a board observer at EarLens, Inc., a privately-held company. Dr. Kherani is also a board observer at Loxo Oncology, Inc. Dr. Kherani received his M.D. from Duke, and his B.S. in Biology and A.B. in Economics from Duke.
- Paul A. LaViolette
-
Paul A. LaViolette，自2013年9月以来是本公司的董事长。他是一家医疗设备价值型基金- SV Life Sciences Fund IV, L.P. SVLS的经营合伙人和首席运营官。于2009年加入SVLS的他，拥有着超过33年的全球医疗技术管理经验。在加入SVLS之前，他曾在一家80亿美元资产的医疗设备领导者- Boston Scientific Corporation (BSC)担任首席运营官。在BSC的15年里，他曾担任首席运营官、集团总裁、心脏内科总裁和国际总裁。他曾整合了12个收购，以及领导产品开发、运营和全球商业组织。此前曾在CR Bard担任市场营销和综合管理职位，以及曾在Kendall (Covidien)担任各种市场营销职位。他目前在Baxano Surgical股份有限公司和Thoratec公司的董事会任职（这两家公司都是上市公司）。此外，他还在以下上市公司的董事会任职：Cardiofocus股份有限公司、CardioKinetix股份有限公司、Coridea NC2股份有限公司、CSA Medical股份有限公司、DC Devices股份有限公司、Direct Flow Medical股份有限公司和ValenTx股份有限公司；以及在医疗设备制造商协会（Medical Device Manufacturers Associatio）的理事会任职。他是从Fairfield大学获得他的心理学学士学位，以及从Boston学院获得他的工商管理硕士学位的。
Paul A. LaViolette has served as Chairman of our Board since September 2013. Mr. LaViolette is Managing Partner and Chief Operating Officer at SV Life Sciences SVLS, a medical device value fund. He joined SVLS in 2009 and has over 33 years of global medical technology management experience. Prior to joining SVLS, Mr. LaViolette was most recently Chief Operating Officer at Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he served as COO, Group President, President-Cardiology and President-International. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. Mr. LaViolette previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien). Mr. LaViolette serves on the boards of Axon Therapies, Bardy Diagnostics, Inc., Cardiofocus, Inc., CardioKinetix, Inc., Cibiem, Inc., CSA Medical Inc., Corvia Medical, Inc., Endotronix, Inc., Soffio Medical, Inc., ValenTx, Inc., Ximedica, each of which are privately-held, as well as the Medical Device Manufacturers Association. Mr. LaViolette received his B.A. in Psychology from Fairfield University and his MBA from Boston College. - Paul A. LaViolette，自2013年9月以来是本公司的董事长。他是一家医疗设备价值型基金- SV Life Sciences Fund IV, L.P. SVLS的经营合伙人和首席运营官。于2009年加入SVLS的他，拥有着超过33年的全球医疗技术管理经验。在加入SVLS之前，他曾在一家80亿美元资产的医疗设备领导者- Boston Scientific Corporation (BSC)担任首席运营官。在BSC的15年里，他曾担任首席运营官、集团总裁、心脏内科总裁和国际总裁。他曾整合了12个收购，以及领导产品开发、运营和全球商业组织。此前曾在CR Bard担任市场营销和综合管理职位，以及曾在Kendall (Covidien)担任各种市场营销职位。他目前在Baxano Surgical股份有限公司和Thoratec公司的董事会任职（这两家公司都是上市公司）。此外，他还在以下上市公司的董事会任职：Cardiofocus股份有限公司、CardioKinetix股份有限公司、Coridea NC2股份有限公司、CSA Medical股份有限公司、DC Devices股份有限公司、Direct Flow Medical股份有限公司和ValenTx股份有限公司；以及在医疗设备制造商协会（Medical Device Manufacturers Associatio）的理事会任职。他是从Fairfield大学获得他的心理学学士学位，以及从Boston学院获得他的工商管理硕士学位的。
- Paul A. LaViolette has served as Chairman of our Board since September 2013. Mr. LaViolette is Managing Partner and Chief Operating Officer at SV Life Sciences SVLS, a medical device value fund. He joined SVLS in 2009 and has over 33 years of global medical technology management experience. Prior to joining SVLS, Mr. LaViolette was most recently Chief Operating Officer at Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he served as COO, Group President, President-Cardiology and President-International. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. Mr. LaViolette previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien). Mr. LaViolette serves on the boards of Axon Therapies, Bardy Diagnostics, Inc., Cardiofocus, Inc., CardioKinetix, Inc., Cibiem, Inc., CSA Medical Inc., Corvia Medical, Inc., Endotronix, Inc., Soffio Medical, Inc., ValenTx, Inc., Ximedica, each of which are privately-held, as well as the Medical Device Manufacturers Association. Mr. LaViolette received his B.A. in Psychology from Fairfield University and his MBA from Boston College.
- David B. Milne
-
David B. Milne，是SVLS的一位管理合伙人。于2005年加入SVLS；曾在数家大型公共和私营医疗技术公司工作的他，拥有着25年的医疗行业经验。1999年一直到2005年加入SVLS之前，他在BSC担任商业开发副总裁，负责着超过50个交易额超过近20亿美元的收购、股权投资和发展伙伴关系。他目前分别在AqueSys, Inc., Altura Medical股份有限公司、EBR Systems股份有限公司、Entellus Medical股份有限公司、ReShape Medical股份有限公司和Spinal Kinetics有限责任公司的董事会任职。此前曾在Scimed Life Systems、Becton Dickinson 和Parker Laboratories工作。他拥有从New York大学获得的市场营销/财务专业工商管理硕士学位，以及从Rutgers大学获得的生物学学士学位。
David B. Milne has served as a member of the company's Board of Directors since August 2006. Mr. Milne is a Venture Partner at SV Life Sciences Advisers, LLC, or SVLS, which is a life sciences venture capital firm. From February 2015 to December 2016 Mr. Milne served as a Managing Partner of SVLS. From 1999 until joining SVLS in February 2005 he held the position of Vice President of Corporate Business Development at Boston Scientific Corporation. Mr. Milne currently sits on the board of directors of EBR Systems, Inc., ReShape Medical, Inc., and Spinal Kinetics, Inc., all privately held companies, and TransEnterix, Inc., a publicly traded medical device company. Mr. Milne serves on the audit committee and the corporate governance and nominating committee of TransEnterix. In addition, Mr. Milne previously served on the board of directors AqueSys, Inc., Altura Medical, Inc., Sadra Medical, Inc., MindFrame, Inc., NovaLign, Inc. and CardioMind, Inc., all privately held companies, and Lombard Medical, a publicly traded medical device company. Previously Mr. Milne worked at SCIMED Life Systems, Inc., Becton, Dickinson and Company and Parker Laboratories, Inc. He holds a B.S. in Biology from Rutgers University and an M.B.A. in Marketing/Finance from New York University. - David B. Milne，是SVLS的一位管理合伙人。于2005年加入SVLS；曾在数家大型公共和私营医疗技术公司工作的他，拥有着25年的医疗行业经验。1999年一直到2005年加入SVLS之前，他在BSC担任商业开发副总裁，负责着超过50个交易额超过近20亿美元的收购、股权投资和发展伙伴关系。他目前分别在AqueSys, Inc., Altura Medical股份有限公司、EBR Systems股份有限公司、Entellus Medical股份有限公司、ReShape Medical股份有限公司和Spinal Kinetics有限责任公司的董事会任职。此前曾在Scimed Life Systems、Becton Dickinson 和Parker Laboratories工作。他拥有从New York大学获得的市场营销/财务专业工商管理硕士学位，以及从Rutgers大学获得的生物学学士学位。
- David B. Milne has served as a member of the company's Board of Directors since August 2006. Mr. Milne is a Venture Partner at SV Life Sciences Advisers, LLC, or SVLS, which is a life sciences venture capital firm. From February 2015 to December 2016 Mr. Milne served as a Managing Partner of SVLS. From 1999 until joining SVLS in February 2005 he held the position of Vice President of Corporate Business Development at Boston Scientific Corporation. Mr. Milne currently sits on the board of directors of EBR Systems, Inc., ReShape Medical, Inc., and Spinal Kinetics, Inc., all privately held companies, and TransEnterix, Inc., a publicly traded medical device company. Mr. Milne serves on the audit committee and the corporate governance and nominating committee of TransEnterix. In addition, Mr. Milne previously served on the board of directors AqueSys, Inc., Altura Medical, Inc., Sadra Medical, Inc., MindFrame, Inc., NovaLign, Inc. and CardioMind, Inc., all privately held companies, and Lombard Medical, a publicly traded medical device company. Previously Mr. Milne worked at SCIMED Life Systems, Inc., Becton, Dickinson and Company and Parker Laboratories, Inc. He holds a B.S. in Biology from Rutgers University and an M.B.A. in Marketing/Finance from New York University.
- Todd M. Pope
-
Todd M. Pope，于2013年9月3日Merger的完成之时，成为本公司的总裁和首席执行官。在Merger之前，他从2008年9月起担任TransEnterix Surgical的总裁和首席执行官。他曾在医疗设备行业担任了超过20年的重要领导职位。在加入TransEnterix Surgical之前，曾是Johnson & Johnson医疗设备公司的数十亿美元资产公司- Cordis的全球总裁。此前曾在Johnson & Johnson 和BSC担任许多领导职位。他是从教堂山（Chapel Hill）北卡莱罗纳大学（University of North Carolina）获得他的学士学位的；目前在Kenan-Flagler大学监事会以及教育基金会执行委员会任职。
Todd M. Pope became our President and Chief Executive Officer on September 3 2013 in connection with the consummation of the Merger. Prior to the Merger, he was the president and chief executive officer of TransEnterix Surgical, Inc., one of the parties to the Merger, from September 2008. Mr. Pope has spent more than 25 years working in key leadership positions within the medical device industry. Prior to joining TransEnterix Surgical, Mr. Pope served as worldwide president of Cordis, a multi-billion-dollar division within Johnson & Johnson’s medical device business. Mr. Pope previously held a number of leadership positions within Johnson & Johnson and Boston Scientific Corporation. Mr. Pope received his bachelor’s degree from University of North Carolina at Chapel Hill, and currently serves on the University’s Kenan-Flagler Board of Visitors, and Educational Foundation Executive Board. - Todd M. Pope，于2013年9月3日Merger的完成之时，成为本公司的总裁和首席执行官。在Merger之前，他从2008年9月起担任TransEnterix Surgical的总裁和首席执行官。他曾在医疗设备行业担任了超过20年的重要领导职位。在加入TransEnterix Surgical之前，曾是Johnson & Johnson医疗设备公司的数十亿美元资产公司- Cordis的全球总裁。此前曾在Johnson & Johnson 和BSC担任许多领导职位。他是从教堂山（Chapel Hill）北卡莱罗纳大学（University of North Carolina）获得他的学士学位的；目前在Kenan-Flagler大学监事会以及教育基金会执行委员会任职。
- Todd M. Pope became our President and Chief Executive Officer on September 3 2013 in connection with the consummation of the Merger. Prior to the Merger, he was the president and chief executive officer of TransEnterix Surgical, Inc., one of the parties to the Merger, from September 2008. Mr. Pope has spent more than 25 years working in key leadership positions within the medical device industry. Prior to joining TransEnterix Surgical, Mr. Pope served as worldwide president of Cordis, a multi-billion-dollar division within Johnson & Johnson’s medical device business. Mr. Pope previously held a number of leadership positions within Johnson & Johnson and Boston Scientific Corporation. Mr. Pope received his bachelor’s degree from University of North Carolina at Chapel Hill, and currently serves on the University’s Kenan-Flagler Board of Visitors, and Educational Foundation Executive Board.
- William N. Starling
-
William N. Starling，是一家于2006年创立的生命科学风险投资公司- Synergy Life Science Partners, LP的总经理；2001年是一家恒温箱新生命科学公司- Synecor有限责任公司的首席执行官和联合创始人。作为Synecor的首席执行官，他是BaroSense股份有限公司、Bioerodible Vascular Solutions股份有限公司、InnerPulse股份有限公司、TransEnterix、Interventional Autonomics 公司、NeuroTronik有限公司和Aegis Surgical有限公司的联合创始人。他目前是Aegis Surgical 和Interventional Autonomics公司的总裁和首席执行官；以及是EBR Systems股份有限公司和iRhythm Technologies的董事会成员，这些公司都是私营的。他是在American Edwards Laboratories开始他的医疗技术设备行业职业生涯的，随后成为Advanced Cardiovascular Systems股份有限公司的创始管理团队成员和市场营销总监；Ventritex股份有限公司的联合创始人、副总裁和董事会成员；以及Cardiac Pathways公司的联合创始人、董事长和总裁/首席执行官。他是从教堂山（Chapel Hill）北卡莱罗纳大学（University of North Carolina）获得他的工商管理学士学位，以及从南加州大学（University of Southern California）获得他的工商管理硕士学位的。
William N. Starling is Managing Director of Synergy Life Science Partners, LP, a life science venture capital firm founded in 2006 and Chief Executive Officer and co-founder, in 2000 of Synecor, LLC, an incubator/accelerator for new medical device companies. As CEO of Synecor, Mr. Starling is a cofounder of BaroSense Inc., Bioerodible Vascular Solutions, Inc., InnerPulse, Inc., TransEnterix, Interventional Autonomics Corporation, NeuroTronik Limited, Aegis Surgical, Limited, and Atrius Limited, all of which are privately-held companies. Mr. Starling currently serves as CEO of Aegis Surgical and Atrius Limited, and as a board member of EBR Systems, Inc., which are privately-held. He began his career in the medical technology device industry at American Edwards Laboratories and subsequently was part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc.; a cofounder, Vice President and board member of Ventritex, Inc.; and a cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation. Mr. Starling received his BSBA degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California. - William N. Starling，是一家于2006年创立的生命科学风险投资公司- Synergy Life Science Partners, LP的总经理；2001年是一家恒温箱新生命科学公司- Synecor有限责任公司的首席执行官和联合创始人。作为Synecor的首席执行官，他是BaroSense股份有限公司、Bioerodible Vascular Solutions股份有限公司、InnerPulse股份有限公司、TransEnterix、Interventional Autonomics 公司、NeuroTronik有限公司和Aegis Surgical有限公司的联合创始人。他目前是Aegis Surgical 和Interventional Autonomics公司的总裁和首席执行官；以及是EBR Systems股份有限公司和iRhythm Technologies的董事会成员，这些公司都是私营的。他是在American Edwards Laboratories开始他的医疗技术设备行业职业生涯的，随后成为Advanced Cardiovascular Systems股份有限公司的创始管理团队成员和市场营销总监；Ventritex股份有限公司的联合创始人、副总裁和董事会成员；以及Cardiac Pathways公司的联合创始人、董事长和总裁/首席执行官。他是从教堂山（Chapel Hill）北卡莱罗纳大学（University of North Carolina）获得他的工商管理学士学位，以及从南加州大学（University of Southern California）获得他的工商管理硕士学位的。
- William N. Starling is Managing Director of Synergy Life Science Partners, LP, a life science venture capital firm founded in 2006 and Chief Executive Officer and co-founder, in 2000 of Synecor, LLC, an incubator/accelerator for new medical device companies. As CEO of Synecor, Mr. Starling is a cofounder of BaroSense Inc., Bioerodible Vascular Solutions, Inc., InnerPulse, Inc., TransEnterix, Interventional Autonomics Corporation, NeuroTronik Limited, Aegis Surgical, Limited, and Atrius Limited, all of which are privately-held companies. Mr. Starling currently serves as CEO of Aegis Surgical and Atrius Limited, and as a board member of EBR Systems, Inc., which are privately-held. He began his career in the medical technology device industry at American Edwards Laboratories and subsequently was part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc.; a cofounder, Vice President and board member of Ventritex, Inc.; and a cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation. Mr. Starling received his BSBA degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California.
高管简历
中英对照 | 中文 | 英文- Anthony Fernando
Anthony Fernando，曾一直担任我们的首席技术官（2016年1月19日以来），也曾担任国际开发副总裁（2015年8月至2016年1月19日担任首席技术官）。此前，他曾担任Stryker Singapore Pvt. Ltd（全球医疗技术公司）的国际创新和技术副总裁（从2013年10月到2015年7月）。他曾担任Becton Dickinson & Company（全球医疗技术公司，专注于开发、制造和销售医疗器械）的大亚洲研发主管（2010年8月至2013年10月）。从2007年7月到2010年7月，他曾担任Perkinelmer Singapore Pvt. Ltd.的亚洲环境卫生研发董事。直到2015年7月，他也曾担任Stryker India Private Limited、Stryker Global Technology Center India的董事。
- Anthony Fernando，曾一直担任我们的首席技术官（2016年1月19日以来），也曾担任国际开发副总裁（2015年8月至2016年1月19日担任首席技术官）。此前，他曾担任Stryker Singapore Pvt. Ltd（全球医疗技术公司）的国际创新和技术副总裁（从2013年10月到2015年7月）。他曾担任Becton Dickinson & Company（全球医疗技术公司，专注于开发、制造和销售医疗器械）的大亚洲研发主管（2010年8月至2013年10月）。从2007年7月到2010年7月，他曾担任Perkinelmer Singapore Pvt. Ltd.的亚洲环境卫生研发董事。直到2015年7月，他也曾担任Stryker India Private Limited、Stryker Global Technology Center India的董事。
- Anthony Fernando has served as our Chief Technology Officer since January 19 2016 and served as Vice President, International Development, from August 2015 until his appointment as Chief Technology Officer on January 19 2016. Previously, Mr. Fernando served as Vice President, Innovation and Technology, International, of Stryker Singapore Pvt. Ltd, a global medical technology company, from October 2013 until July 2015. From August 2010 until October 2013 Mr. Fernando served as Director of Research and Development, greater Asia, for Becton Dickinson & Company, a global medical technology company engaged in the development, manufacture and sale of medical devices. From July 2007 until July 2010 Mr. Fernando served as the Director of Research and Development, Asia - Environmental Health, at Perkinelmer Singapore Pvt. Ltd. Until July 2015 Mr. Fernando also served as a director of Stryker India Private Limited and Stryker Global Technology Center India.
- Joseph P. Slattery
Joseph P. Slattery从2007年11月开始一直担任我司董事会董事。Slattery先生担任TranS1 Inc.的执行副总裁兼首席财务官，这是一家上市的医疗设备公司，从2007年11月到2010年4月，担任TranS1的审计委员会主席。在这之前，Slattery先生担任Digene Corporation的首席财务官兼高级副总裁，这是一家公众所有的医疗诊断公司，其于2007年7月被Qin, N.V.收购。于2006年担任首席财务官前，Slattery先生从2002年开始担任Digene的财务与信息系统部的高级副总裁，在这之前，担任过财务部的财务总管兼副总裁。Slattery先生在本特利大学(Bentley University)获得会计学理学学士学位，并是一位注册会计师。
- Joseph P. Slattery从2007年11月开始一直担任我司董事会董事。Slattery先生担任TranS1 Inc.的执行副总裁兼首席财务官，这是一家上市的医疗设备公司，从2007年11月到2010年4月，担任TranS1的审计委员会主席。在这之前，Slattery先生担任Digene Corporation的首席财务官兼高级副总裁，这是一家公众所有的医疗诊断公司，其于2007年7月被Qin, N.V.收购。于2006年担任首席财务官前，Slattery先生从2002年开始担任Digene的财务与信息系统部的高级副总裁，在这之前，担任过财务部的财务总管兼副总裁。Slattery先生在本特利大学(Bentley University)获得会计学理学学士学位，并是一位注册会计师。
- Joseph P. Slattery has served as a member of our board of directors since May 2019. Since October 2013 he has served as Executive Vice President and Chief Financial Officer of TransEnterix, Inc., a medical device company. Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical Inc., a minimally invasive spinal surgery company, from April 2010 to September 2013. From February 1996 to August 2007 he served in finance and accounting roles including Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp., a molecular diagnostics company acquired by Qiagen, N.V. in 2007. Currently, he serves on the boards of directors of Replimune Group, Inc. and certain private companies. Mr. Slattery earned a B.S. in Accounting from Bentley University and is a certified public accountant.
- Todd M. Pope
Todd M. Pope，于2013年9月3日Merger的完成之时，成为本公司的总裁和首席执行官。在Merger之前，他从2008年9月起担任TransEnterix Surgical的总裁和首席执行官。他曾在医疗设备行业担任了超过20年的重要领导职位。在加入TransEnterix Surgical之前，曾是Johnson & Johnson医疗设备公司的数十亿美元资产公司- Cordis的全球总裁。此前曾在Johnson & Johnson 和BSC担任许多领导职位。他是从教堂山（Chapel Hill）北卡莱罗纳大学（University of North Carolina）获得他的学士学位的；目前在Kenan-Flagler大学监事会以及教育基金会执行委员会任职。
- Todd M. Pope，于2013年9月3日Merger的完成之时，成为本公司的总裁和首席执行官。在Merger之前，他从2008年9月起担任TransEnterix Surgical的总裁和首席执行官。他曾在医疗设备行业担任了超过20年的重要领导职位。在加入TransEnterix Surgical之前，曾是Johnson & Johnson医疗设备公司的数十亿美元资产公司- Cordis的全球总裁。此前曾在Johnson & Johnson 和BSC担任许多领导职位。他是从教堂山（Chapel Hill）北卡莱罗纳大学（University of North Carolina）获得他的学士学位的；目前在Kenan-Flagler大学监事会以及教育基金会执行委员会任职。
- Todd M. Pope became our President and Chief Executive Officer on September 3 2013 in connection with the consummation of the Merger. Prior to the Merger, he was the president and chief executive officer of TransEnterix Surgical, Inc., one of the parties to the Merger, from September 2008. Mr. Pope has spent more than 25 years working in key leadership positions within the medical device industry. Prior to joining TransEnterix Surgical, Mr. Pope served as worldwide president of Cordis, a multi-billion-dollar division within Johnson & Johnson’s medical device business. Mr. Pope previously held a number of leadership positions within Johnson & Johnson and Boston Scientific Corporation. Mr. Pope received his bachelor’s degree from University of North Carolina at Chapel Hill, and currently serves on the University’s Kenan-Flagler Board of Visitors, and Educational Foundation Executive Board.